Onpattro

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Thu, 10/12/23 - 05:32 pm
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Thu, 09/14/23 - 09:59 am
Alnylam
FDA
Onpattro
ATTR-CM
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Tue, 09/12/23 - 07:06 pm
Alnylam
FDA
ATTR-CM
Onpattro
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Clinical Trials Arena
Mon, 05/22/23 - 10:11 am
Alnylam Pharmaceuticals
Onpattro
clinical trials
transthyretin amyloidosis with cardiomyopathy
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
Mon, 03/27/23 - 10:22 am
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Mon, 10/3/22 - 11:41 pm
Alnylam
Onpattro
Pfizer
ATTR-CM
Alnylam details anticipated results from heart disease drug trial
BioPharma Dive
Thu, 09/8/22 - 10:47 am
Alnylam
clinical trials
Onpattro
transthyretin amyloidosis with cardiomyopathy
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
MedCity News
Thu, 08/4/22 - 11:09 am
Alnylam
Pfizer
Onpattro
hATTR
Alnylam reveals longer wait for anticipated drug trial results
BioPharma Dive
Thu, 07/28/22 - 12:25 pm
Alnylam
earnings
clinical trials
Onpattro
Alnylam shoots for the heart
EP Vantage
Thu, 05/19/22 - 10:16 am
Alnylam
Onpattro
ATTR amyloidosis
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
BioPharma Dive
Tue, 04/26/22 - 10:31 am
Alnylam
clinical trials
Onpattro
transthyretin amyloid cardiomyopathy
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
EP Vantage
Tue, 01/25/22 - 10:41 am
Alnylam
vutrisiran
Onpattro
hereditary ATTR amyloidosis
AAN 2021 – Helios backs Alnylam’s sunny forecasts
EP Vantage
Wed, 04/21/21 - 10:28 am
Alnylam
AAN
vutrisiran
Onpattro
hATTR amyloidosis
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Thu, 03/26/20 - 10:22 am
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
Alnylam posts strong Onpattro sales as competition heats up
Biopharma Dive
Thu, 05/2/19 - 08:12 pm
Alnylam
Onpattro
earnings
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva

Pages